India · Delayed Price · Currency is INR Deepak Nitrite Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY 2026 delivered 3% revenue growth and 16% higher EBITDA year-on-year, with margin improvement despite global pricing pressures. Vertical integration and new capacity ramp-ups are expected to drive margin normalization and growth in Q4, supported by favorable trade policy shifts.
-
Q2 FY2026 saw sequential revenue and margin growth, with phenolics outperforming and advanced intermediates under pressure from tariffs and dumping. Major projects and new products are set to drive growth, with most new capacities to be commissioned by June 2026.
-
Q1 FY26 saw resilient performance with consolidated revenue of INR 1,897 crore and EBITDA up 11% sequentially, driven by phenolics and cost optimization, despite challenges in agrochemical intermediates. Major CapEx and integration projects are on track, with new product launches and backward integration expected to boost growth and margins from Q3 FY26.
Fiscal Year 2025
-
FY 2025 saw 8% revenue growth to INR 8,366 crore despite global headwinds, with strong Q4 recovery and robust domestic demand. Major CapEx projects and renewable energy transition are underway, positioning for improved profitability and growth in FY 2026.
-
Q3 saw a 5% YoY revenue decline and margin compression due to weak agrochemical demand, high raw material costs, and project delays. Recovery is expected from Q4 as demand stabilizes, new capacities come online, and cost optimization measures take effect.
-
Announced a ₹5,000 crore polycarbonate resin plant investment with Trinseo technology, driving integration and future growth. Q2 revenue rose 14% year-on-year, with strong phenolics performance and resilient margins. Multiple projects and R&D center on track to boost margins and innovation.
-
Q1 FY25 saw 21% revenue and 36% EBITDA growth year-over-year, led by strong phenolics performance and robust domestic demand. Expansion projects and new product launches are on track, with recovery in key segments expected from Q3 onwards.